- Home
- ZH vs ABEO Comparison
ZH vs ABEO Comparison
Compare ZH & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZH
- ABEO
- Stock Information
- Founded
- ZH 2011
- ABEO 1974
- Country
- ZH China
- ABEO United States
- Employees
- ZH N/A
- ABEO N/A
- Industry
- ZH Business Services
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- ZH Consumer Discretionary
- ABEO Health Care
- Exchange
- ZH Nasdaq
- ABEO Nasdaq
- Market Cap
- ZH 421.4M
- ABEO 350.2M
- IPO Year
- ZH 2021
- ABEO 1980
- Fundamental
- Price
- ZH $5.01
- ABEO $6.83
- Analyst Decision
- ZH Strong Buy
- ABEO Strong Buy
- Analyst Count
- ZH 1
- ABEO 6
- Target Price
- ZH $4.70
- ABEO $18.17
- AVG Volume (30 Days)
- ZH 417.0K
- ABEO 691.9K
- Earning Date
- ZH 08-27-2025
- ABEO 08-14-2025
- Dividend Yield
- ZH N/A
- ABEO N/A
- EPS Growth
- ZH N/A
- ABEO N/A
- EPS
- ZH 0.22
- ABEO 0.99
- Revenue
- ZH $439,821,184.00
- ABEO $400,000.00
- Revenue This Year
- ZH N/A
- ABEO N/A
- Revenue Next Year
- ZH $7.46
- ABEO $339.63
- P/E Ratio
- ZH $22.66
- ABEO $6.90
- Revenue Growth
- ZH N/A
- ABEO N/A
- 52 Week Low
- ZH $3.13
- ABEO $3.93
- 52 Week High
- ZH $6.32
- ABEO $7.54
- Technical
- Relative Strength Index (RSI)
- ZH 60.50
- ABEO 51.80
- Support Level
- ZH $4.64
- ABEO $6.77
- Resistance Level
- ZH $4.90
- ABEO $7.05
- Average True Range (ATR)
- ZH 0.24
- ABEO 0.25
- MACD
- ZH 0.01
- ABEO -0.04
- Stochastic Oscillator
- ZH 75.44
- ABEO 28.66
About ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.